In comparison to individuals in the trials placebo group.

Cancer risk slightly higher for ladies in discontinued hormone treatment trial A follow up study of participants in the Women’s Wellness Initiative clinical trial led by a University of NEW YORK at Chapel Hill researcher has discovered that women who were taking the combined hormone therapy of estrogen plus progestin may have an elevated risk of cancer because the intervention was stopped, in comparison to individuals in the trial’s placebo group. The study’s lead author is Dr www.suhagra100mg.net/suhagra-vs-silagra.html . Gerardo Heiss, a Kenan professor of epidemiology in the UNC College of Public Wellness.